Beam Therapeutics Inc. Business Combination, Contingent Consideration, Liability, Current
Beam Therapeutics Inc. (BEAM) had Business Combination, Contingent Consideration, Liability, Current of $2.77 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Business Combination, Contingent Consideration, Liability, Current $2.77M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Current $2.70M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $2.71M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $1.19M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2026-06-30 | $2.77M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.71M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $1.19M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |